Egyptian International Pharmaceutical Investments (CAI:PHAR) Total Assets : E£9,979 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments Total Assets?

Egyptian International Pharmaceutical Investments's Total Assets for the quarter that ended in Dec. 2023 was E£9,979 Mil.

Warning Sign:

If a company builds assets at 44.5% a year, faster than its revenue growth rate of 8.9% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Egyptian International Pharmaceutical Investments's average Total Assets Growth Rate was 47.90% per year. During the past 3 years, the average Total Assets Growth Rate was 29.30% per year. During the past 5 years, the average Total Assets Growth Rate was 44.50% per year. During the past 10 years, the average Total Assets Growth Rate was 16.00% per year.

During the past 13 years, Egyptian International Pharmaceutical Investments's highest 3-Year average Total Assets Growth Rate was 71.30%. The lowest was -23.00%. And the median was 9.50%.

Total Assets is connected with ROA %. Egyptian International Pharmaceutical Investments's annualized ROA % for the quarter that ended in Dec. 2023 was 10.33%. Total Assets is also linked to Revenue through Asset Turnover. Egyptian International Pharmaceutical Investments's Asset Turnover for the quarter that ended in Dec. 2023 was 0.16.

Egyptian International Pharmaceutical Investments Total Assets Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments Total Assets Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

4,414.95

5,032.61

5,234.89

6,773.91

9,978.78

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															6,773.91	7,781.04	8,850.82	9,742.75	9,978.78

Egyptian International Pharmaceutical Investments Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Egyptian International Pharmaceutical Investments's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	4260.803	+	5717.98
	=	9,979

Egyptian International Pharmaceutical Investments's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	4260.803	+	5717.98
	=	9,979

Egyptian International Pharmaceutical Investments (CAI:PHAR) Total Assets Explanation

Total Assets is connected with ROA %.

Egyptian International Pharmaceutical Investments's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	1018.4	/	( (9742.746	+	9978.783)	/ 2 )
	=	1018.4	/	9860.7645
	=	10.33 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Egyptian International Pharmaceutical Investments's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	1550.576	/	( (9742.746	+	9978.783)	/ 2 )
=	1550.576	/	9860.7645
=	0.16

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Egyptian International Pharmaceutical Investments Total Assets Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.